Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Aug 12, 2014
Neuren advances NNZ-2591 towards IND application
Jul 22, 2014
Appendix 3B
Jul 18, 2014
Appendix 4C - quarterly
Jul 17, 2014
US$3m increase to US Army grant and INTREPID outlook update
Jul 10, 2014
Neuren receives ethics approval to start Concussion trial
Jun 26, 2014
Neuren completes enrolment in Phase 2 trial in Rett Syndrome
Jun 25, 2014
Appendix 3B
Jun 23, 2014
Neuren appoints CMC expert to leadership team
Jun 04, 2014
Neuren receives new US patent for NNZ-2591
Jun 03, 2014
Appendix 3B
Previous
1
2
3
4
5
Next